(Q38011943)

27 August 2017

MicroRNAs as putative mediators of treatment response in prostate cancer (English)

1 reference

27 August 2017

1 reference

1 reference

5

1 reference

27 August 2017

Fardod O'Kelly

1

1 reference

27 August 2017

Laure Marignol

2

1 reference

27 August 2017

Armelle Meunier

3

1 reference

27 August 2017

Thomas H Lynch

4

1 reference

27 August 2017

Donal Hollywood

6

1 reference

27 August 2017

language of work or name

English

0 references

publication date

22 May 2012

1 reference

27 August 2017

Nature Reviews Urology

1 reference

27 August 2017

9

1 reference

27 August 2017

397-407

1 reference

27 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2012.104

27 August 2017

0 references

cites work

Estimates of the cancer incidence and mortality in Europe in 2006.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

International trends and patterns of prostate cancer incidence and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Natural History of Early, Localized Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Predicting 15-year prostate cancer specific mortality after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MiRNAs as biomarkers and therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

21 January 2018

RNA silencing in plants

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA expression profiles classify human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Circulating microRNAs as stable blood-based markers for cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA in prostate, bladder, and kidney cancer: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

The function of microRNAs, small but potent molecules, in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA regulation of DNA repair gene expression in hypoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

The N domain of Argonaute drives duplex unwinding during RISC assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Towards the definition of prostate cancer-related microRNAs: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNAs: key players in carcinogenesis and novel therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Therapeutic potential for microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MTar: a computational microRNA target prediction architecture for human transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Fast and effective prediction of microRNA/target duplexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Desperately seeking microRNA targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNAs: novel biomarkers for human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Epigenetics in prostate cancer: biologic and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Intracellular adaptor molecules and AR signalling in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

DNA methylation and gene silencing in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

The emerging roles of DNA methylation in the clinical management of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Towards the human cancer epigenome: a first draft of histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2α gene is associated with cisplatin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

An E2F/miR-20a autoregulatory feedback loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Castration-resistant prostate cancer: locking up the molecular escape routes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

miR-21: an oncomir on strike in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Loss of mir-146a function in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

miR 488* inhibits androgen receptor expression in prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Androgen regulation of micro-RNAs in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Association of reactive oxygen species levels and radioresistance in cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MiR-34, SIRT1 and p53: the feedback loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Radiation modulation of microRNA in prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Hypoxia in prostate cancer: a powerful shield against tumour destruction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Tumor hypoxia and malignant progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

The role of p53 in hypoxia-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

miR-210: the master hypoxamir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNAs as new therapeutic targets and tools in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Chromosome 8 markers of metastatic prostate cancer in African American men: gain of the MIR151 gene and loss of the NKX3-1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Circulating microRNAs (miRNA) in serum of patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA-21 targets tumor suppressor genes in invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

A microRNA expression signature of human solid tumors defines cancer gene targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

miR-449a targets HDAC-1 and induces growth arrest in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Evidence linking CD44-positive cells and gemcitabine resistance in pancreatic cancer cells: need for further substantiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Gene networks and microRNAs implicated in aggressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA regulation of growth factor receptor signaling in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Dysregulation of the mitogen granulin in human cancer through the miR-15/107 microRNA gene group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Optimal measure of PSA kinetics to identify prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

The functions of animal microRNAs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

DBD--taxonomically broad transcription factor predictions: new content and functionality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

Circulating miRNAs are correlated with tumor progression in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.104

The microRNA.org resource: targets and expression

31 March 2020

1 reference

12 December 2020

miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions

1 reference

12 December 2020

Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence

1 reference

12 December 2020

Immunoexpressions of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates

1 reference

12 December 2020

Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features

1 reference

12 December 2020

MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs

1 reference

12 December 2020

MicroRNAs and prostate cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2012.104

1 reference

Dimensions Publication ID

27 August 2017

0 references

1 reference